Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

INTRODUCTION: First-line treatment of EGFR-mutated NSCLC with erlotinib plus antiangiogenic inhibitor exhibits promising results. However, the efficacy of this combination has not been fully investigated. Therefore, we evaluated the efficacy and safety of osimertinib plus bevacizumab in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibino, Makoto, Hiranuma, Osamu, Takemura, Yoshizumi, Katayama, Yuki, Chihara, Yusuke, Harada, Taishi, Fujita, Kohei, Kita, Toshiyuki, Tamiya, Nobuyo, Tsuda, Takeshi, Shiotsu, Shinsuke, Tamura, Yukihiro, Aoyama, Takashi, Nakamura, Yoichi, Terashima, Masaaki, Morimoto, Yoshie, Nagata, Kazuhiro, Yoshimura, Kenichi, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692038/
https://www.ncbi.nlm.nih.gov/pubmed/36438852
http://dx.doi.org/10.1016/j.jtocrr.2022.100424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692038/
https://www.ncbi.nlm.nih.gov/pubmed/36438852
http://dx.doi.org/10.1016/j.jtocrr.2022.100424

Ejemplares similares